DE69719994T2 - Verwendung von genistein als vorbeugendes mittel gegen durch ultraviolette strahlung verursachte hautschäden und krebs - Google Patents

Verwendung von genistein als vorbeugendes mittel gegen durch ultraviolette strahlung verursachte hautschäden und krebs

Info

Publication number
DE69719994T2
DE69719994T2 DE69719994T DE69719994T DE69719994T2 DE 69719994 T2 DE69719994 T2 DE 69719994T2 DE 69719994 T DE69719994 T DE 69719994T DE 69719994 T DE69719994 T DE 69719994T DE 69719994 T2 DE69719994 T2 DE 69719994T2
Authority
DE
Germany
Prior art keywords
genistein
skin
use according
umol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69719994T
Other languages
German (de)
English (en)
Other versions
DE69719994D1 (de
Inventor
Huachen Wei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24639167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69719994(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of DE69719994D1 publication Critical patent/DE69719994D1/de
Application granted granted Critical
Publication of DE69719994T2 publication Critical patent/DE69719994T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69719994T 1996-06-07 1997-06-09 Verwendung von genistein als vorbeugendes mittel gegen durch ultraviolette strahlung verursachte hautschäden und krebs Revoked DE69719994T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/657,915 US5824702A (en) 1996-06-07 1996-06-07 Genistein as a preventive against ultraviolet induced skin photodamage and cancer
PCT/US1997/011963 WO1997046208A2 (en) 1996-06-07 1997-06-09 Genistein as a preventive against ultraviolet induced skin photodamage and cancer

Publications (2)

Publication Number Publication Date
DE69719994D1 DE69719994D1 (de) 2003-04-24
DE69719994T2 true DE69719994T2 (de) 2003-09-04

Family

ID=24639167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69719994T Revoked DE69719994T2 (de) 1996-06-07 1997-06-09 Verwendung von genistein als vorbeugendes mittel gegen durch ultraviolette strahlung verursachte hautschäden und krebs

Country Status (11)

Country Link
US (1) US5824702A (enExample)
EP (1) EP0918504B1 (enExample)
JP (1) JP2000511907A (enExample)
AT (1) ATE234599T1 (enExample)
AU (1) AU716131B2 (enExample)
CA (1) CA2257579C (enExample)
DE (1) DE69719994T2 (enExample)
DK (1) DK0918504T3 (enExample)
ES (1) ES2188963T3 (enExample)
PT (1) PT918504E (enExample)
WO (1) WO1997046208A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333624T2 (de) 1992-05-19 2005-09-15 Novogen Research Pty. Ltd., North Ryde Verwendung von isoflavon phyto-östrogen extrakten von soja oder klee
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US20050058709A1 (en) * 1997-06-04 2005-03-17 Fisher Gary J. Methods for inhibiting photoaging of human skin using orally-administered agent
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
US8039026B1 (en) 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
AUPP112497A0 (en) 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AU3002299A (en) * 1998-03-16 1999-10-11 Procter & Gamble Company, The Methods for regulating skin appearance
US6683069B1 (en) 1998-04-02 2004-01-27 Regents Of The University Of Michigan Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
TWI234455B (en) * 1998-04-02 2005-06-21 Univ Michigan Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
FR2781154B1 (fr) * 1998-07-15 2001-09-07 Lafon Labor Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
US20040131579A1 (en) * 1998-09-10 2004-07-08 Avon Products, Inc. Method and compositions for reducing dermatological aging and for reducing bruising
US6461627B1 (en) * 1998-10-09 2002-10-08 Kabushiki Kaisha Yakult Honsha Skin preparations for external use
WO2000037072A1 (en) * 1998-12-22 2000-06-29 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
JP2001131081A (ja) 1999-11-09 2001-05-15 Shinei Ferumentekku:Kk スーパーオキサイド消去剤および飲料
JP2001131052A (ja) * 1999-11-09 2001-05-15 Shinei Ferumentekku:Kk 化粧品
WO2001095937A2 (en) * 2000-08-08 2001-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Phytoestrogenic isoflavone compositions
US7655694B2 (en) * 2000-06-14 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
WO2001095901A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
CA2414406A1 (en) * 2000-06-26 2002-01-03 The Regents Of The University Of Michigan Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin
FR2815861B1 (fr) * 2000-10-26 2003-02-28 Oreal Utilisation de l'association d'au moins un carotenoide et d'au moins un isoflavonoide pour traiter les signes cutanes du vieillissement
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
EP1234572B1 (de) 2001-02-26 2013-10-30 Mibelle AG Cosmetics Isoflavon-Aglykone enhaltende Hautbehandlungsmittel
EP1370294A2 (en) * 2001-02-27 2003-12-17 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
US20020160061A1 (en) * 2001-02-28 2002-10-31 Claude Saliou Use of legume products for the treatment of external aggressions
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
JP4901025B2 (ja) * 2001-06-22 2012-03-21 株式会社ナリス化粧品 エラスターゼ阻害剤
JP4901024B2 (ja) * 2001-06-22 2012-03-21 株式会社ナリス化粧品 ８−ＯＨｄＧ（８−ハイドロキシデオキシグアノシン）産生抑制剤
EP1321123A1 (de) * 2001-12-20 2003-06-25 Cognis France S.A. Verwendung eines Extraktes der Pflanze Baptisia tinctoria in einer kosmetischen Zusammensetzung
JP2005535614A (ja) * 2002-06-25 2005-11-24 コズメシューティック ソリューションズ プロプライエタリー リミテッド 局所用美容組成物
AU2002328824A1 (en) * 2002-06-29 2004-01-19 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrate and method for production thereof
DE20213787U1 (de) * 2002-09-04 2002-12-19 Warner-Lambert Co., Morris Plains, N.J. Hautpflegemittel
DE10301631A1 (de) * 2003-01-17 2004-07-29 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Sojabohnenkeimextrakten in Kombination mit Vitamin C und/oder E sowie alpha-Glycosylrutin
US7718813B2 (en) 2003-08-15 2010-05-18 Nature Pure Labs Sw, Inc. Hydrolysis and purification of active plant compounds suitable for topical application
ES2369928T3 (es) * 2005-06-29 2011-12-09 Dsm Ip Assets B.V. Nanopartículas de isoflavonas y su utilización.
JP5129130B2 (ja) * 2005-06-29 2013-01-23 ディーエスエム アイピー アセッツ ビー．ブイ． イソフラボンのナノ粒子を含む局所組成物
US9345649B2 (en) 2006-12-21 2016-05-24 Avon Products, Inc. Cosmetic composition containing novel fractal particle-based gels
FR2915378B1 (fr) * 2007-04-27 2009-08-21 Vincience Sa Utilisation d'un principe actif issu du soja (glycine max l.) pour preparer une composition destinee a proteger les mitochondries
FR2915384B1 (fr) * 2007-04-27 2010-01-15 Vincience Utilisation d'un principe actif issu du soja (glycine maxl.) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs.
FR2915381B1 (fr) * 2007-04-27 2012-06-08 Vincience Utilisation d'un principe actif issu du soja (glycine max l) pour preparer une composition destinee a activer le cytochrome c
TWI411448B (zh) * 2007-12-27 2013-10-11 Avon Prod Inc 適合用於化妝品之光學模糊色素組合物
EP2506829A4 (en) * 2009-12-04 2014-05-14 Avon Prod Inc TOPICAL COMPOSITIONS CONTAINING DERRIS SCANDENS BENTH. AND METHOD FOR SKIN TREATMENT
IT1401364B1 (it) * 2010-07-09 2013-07-18 Rottapharm Spa Composizioni dermocosmetiche per protezione solare
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6061513A (ja) * 1983-09-14 1985-04-09 Sansho Seiyaku Kk 化粧料
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
JPH0784383B2 (ja) * 1991-07-23 1995-09-13 辻本化学工業株式会社 抗発癌プロモーター剤
US5545398A (en) * 1993-01-13 1996-08-13 Perricone; Nicholos V. Method and compositions for topical application to the skin of tocotrienol for prevention and/or treatment of skin damage
JP2605607B2 (ja) * 1993-12-08 1997-04-30 日本電気株式会社 半導体集積回路の故障解析装置
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
DE4432947C2 (de) * 1994-09-16 1998-04-09 New Standard Gmbh Mittel zur Behandlung der Haut und seine Verwendung

Also Published As

Publication number Publication date
DE69719994D1 (de) 2003-04-24
AU3722597A (en) 1998-01-05
US5824702A (en) 1998-10-20
ATE234599T1 (de) 2003-04-15
CA2257579A1 (en) 1997-12-11
DK0918504T3 (da) 2003-06-02
JP2000511907A (ja) 2000-09-12
EP0918504A2 (en) 1999-06-02
PT918504E (pt) 2003-08-29
EP0918504B1 (en) 2003-03-19
AU716131B2 (en) 2000-02-17
WO1997046208A2 (en) 1997-12-11
ES2188963T3 (es) 2003-07-01
WO1997046208A3 (en) 1998-02-19
CA2257579C (en) 2007-08-21

Similar Documents

Publication Publication Date Title
DE69719994T2 (de) Verwendung von genistein als vorbeugendes mittel gegen durch ultraviolette strahlung verursachte hautschäden und krebs
DE69534172T2 (de) Zusammensetzung enthaltend ein nicht photokatalytisches Metalloxid und Tocopherol und ihre dermatologische Verwendung
DE69900081T2 (de) Zusammensetzung zum Aufhellen der Haut und/oder der Haare
DE60306565T2 (de) Zusammensetzungen gegen Krebs zur topischen Anwendung
DE69323733T2 (de) Kosmetische oder pharmazeutische zusammensetzung, die eine kombination aus einem polyphenol und ginkgo-extrakt enthaelt
DE69832637T2 (de) Verwendung von Verbindungen zum Schutz der Haut gegen UV-induzierte Immunsuppression
DE60018881T2 (de) Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
DE69321479T2 (de) Retinol enthaltende kosmetische zusammensetzung
DE69600106T2 (de) Hautdepigmentierungs- und/oder Alterungsschutzmittel und seine Verwendung
DE69725843T2 (de) Mittel zur verwendung in der phototherapeutischen behandlung proliferativer hautstörungen
EP1569724B1 (de) Formulierungen enthaltend melatonin, ginkgo biloba und biotin
DE69720613T2 (de) Neue topische Zusammensetzungen, die Melatonin oder seine Analogen in sehr niedrigen Dosen enthalten, und ihre Verwendung in der Kosmetik
DE69016786T2 (de) Verwendung eines Koleusextrakts zur Hautpigmentierung.
DE60131422T2 (de) Zubereitung enthaltend vitamin-c-bestandteil und pigment
EP0486632B1 (de) Lichtschutz
DE19720339A1 (de) Wirkstoffe und Zubereitungen für die Hautaufhellung und zur Verhinderung der Hautbräunung
EP1327438A1 (de) kosmetische Zubereitung und ihre Verwendung
DE60219432T2 (de) Topische lösung enthaltend ein isoflavon-aglykon
DE60035613T2 (de) Topische,kosmetische und pharmazeutische Mittel,enthaltend spezifische alkoxylierte Diester der Fumarsäure
DE69008293T2 (de) Synergistisches Mittel zur Hautdepigmentierung.
DE60208342T2 (de) Pharmazeutische und kosmetische zusammensetzungen zum schutz der haut gegen sonnenstrahlungsschäden
DE69000960T2 (de) Zusammensetzung zur behandlung von pigmentierung.
DE69822098T2 (de) Sonnenschutzmittel die beschädigte rns fragmente enthalten
DE69329487T2 (de) Mittel zur topischen Anwendung auf der Haut zur Behandlung und/oder zur Verhütung von, durch Strahlen verursachten Hautschäden
DE69231968T2 (de) Behandlung eines durch uv-strahlung verursachten erythems

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation